 |
5 Diseases |  |
11 Trials |
|
11 Trials |  |
982 News |  |
| «12...4567891011121314...2021» |
- |||| Enrollment open, CAR T-Cell Therapy: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 15, 2023
P2, N=396, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting
- Comparison of CAR-T cell-mediated cytotoxicity assays with suspension tumor cells using high-throughput plate-based image cytometry method (Section 30; Poster Board #8) - Mar 14, 2023 - Abstract #AACR2023AACR_6865;
Performing time- and E:T ratio-dependent CAR-T cell-mediated cytotoxicity assays, the GFP-based method demonstrated higher sensitivity in detecting thelevel of cytotoxicity when compared to the CMFDA/DAPI viability method. We have established the criteria and considerations for the selection of cytotoxicity assays that are fit-for-purpose to ensure the results produced are meaningful for the specific testing conditions.
- ||| Clinical: We do a lot of CAR (commercial and investigational) and basically never use Tisa-cel. Off study, Axi-cel or Liso-cel or Tecartus. Early on our experience with Tisa-cel was long production times, lots of “out of spec” products, efficacy no better than the others (Twitter) - Mar 14, 2023
- Breyanzi (lisocabtagene maraleucel) / BMS
Lisocabtagene Maraleucel in Second-Line Large B-Cell Lymphoma: Primary Analysis of Phase 3 TRANSFORM Study (Hall 11B) - Mar 12, 2023 - Abstract #BSH2023BSH_164;
These data reinforce liso-cel as a second-line treatment in patients with refractory or early relapsed LBCL. This study was funded by Celgene, a Bristol-Myers Squibb Company.
- A Disproportionality Analysis of the Serious Adverse Drug Events Associated with Gene Therapy Products Using the FDA Adverse Event Reporting System (FAERS) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2288;
However, the observed relationship between the gene therapies and the adverse events does not necessarily imply causality. Further investigation is needed to assess the potential causal relationship between the gene therapies and the adverse events.
- Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2070;
Compared with other CAR T products, axi-cel had higher all-cause but lower non-CAR T costs. MAB use was common among CAR T patients, with substantial HRU and cost impact.
- Time to Approval of Chimeric Antigen Receptor-T Cells (CAR-T) Therapies Among Nordic Countries () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1383;
MAB use was common among CAR T patients, with substantial HRU and cost impact. To date, six CAR-T therapies (Kymriah
- Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Blood Cancers: A Systematic Review () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1125;
It finds uncertainty was not limited to evidence generation but extended to the affordability of CAR T-cell therapies. Existing reimbursement models for CAR T-cell therapies are not fit for propose.
- Uncovering Prescription Drug Pricing: Insights from Payer Price Transparency Regulations () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_773;
Prescription drug prices negotiated between payers and manufacturers are not yet required for release under the Transparency in Coverage regulations, but are nonetheless beginning to appear in publicly released data. Increased reporting efforts have the potential to inform the industry regarding historically concealed negotiated rates for prescription drugs.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel CAR T-Cell Therapies for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (LBCL) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_442;
Axi-cel is a cost-effective CAR T cell therapy for patients with rrLBCL compared to liso-cel and tisa-cel. More studies based on head-to-head clinical trials are necessary to confirm these findings.
- Characteristics of Patients Treated with CAR-T Therapies across Multiple Indications Utilizing the TriNetX Network () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_423;
More studies based on head-to-head clinical trials are necessary to confirm these findings. Since August 31, 2017, 1,462 patients have been administered CAR-T therapies (Kymriah
- | Journal: CD19 CAR antigen engagement mechanisms and affinity tuning. (Pubmed Central) - Mar 7, 2023
The CAR T cells exhibited different antigen density requirements to trigger cytolysis and differed in their propensity to prompt trogocytosis upon contacting tumor cells. Our work shows how structural information can be applied to tune CAR T cell performance to specific target antigen densities.
- || Breyanzi (lisocabtagene maraleucel) / BMS
It’s hard to say that one co-stimulatory signal is better than another in humans given the number of confounders, which may include the target itself. Someone — ahem — may have proposed a mix of CD28 and 4-1BB CARs in the manner similar to the 1:1 CD4:CD8 ratio of Breyanzi. 😉 (Twitter) - Mar 7, 2023
- | Breyanzi (lisocabtagene maraleucel) / BMS
Journal: Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. (Pubmed Central) - Mar 4, 2023
When evaluated in the second line setting in LBCL, liso-cel demonstrated superior event-free survival (EFS) versus standard of care. While acknowledging that choice of a particular CAR T-cell is based chiefly on familiarity of the treating physician with a specific product, liso-cel definitely represents an important addition to the treatment armamentarium of R/R LBCL whether in the second-line setting or beyond.
- | Breyanzi (lisocabtagene maraleucel) / BMS
Biomarker, Journal, Tumor microenvironment, Gene Signature, Biopsy: Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. (Pubmed Central) - Mar 4, 2023
Further, the majority of T cells in the day 11 samples were endogenous. Gene expression signatures in liso-cel-treated patients with LBCL can inform the development of combination therapies and next-generation CAR T-cell therapies.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis
Symptom Burden, Symptom Management, and Supportive Care Needs Among Tisa-cel and Liso-cel CAR T-cell Patients In Remission: A Qualitative Study (ePoster Station #14) - Feb 28, 2023 - Abstract #ONS2023ONS_369;
Implications: Oncology nurses should continue to assess symptoms among adult CAR T-cell patients in remission and offer supportive care as needed. Future research may determine what patients are more at risk of developing long-term symptoms, to describe symptom trajectory, and develop targeted interventions to reduce symptom burden and meet supportive care needs.
- Breyanzi (lisocabtagene maraleucel) / BMS
Changing Lanes: CAR T-cell therapy Turns to the Ambulatory Care Setting (ePoster Station #4) - Feb 28, 2023 - Abstract #ONS2023ONS_289;
Interventions We selected the CAR T-cell product Lisocabtagene Maraleucel, for use after two lines of therapy, as the first product to administer in the ambulatory setting based on its safety profile...Outpatient education and administration of this therapy shows promising outcomes for decreasing hospitalization and increasing patient satisfaction without compromising safety. Additional considerations are to discuss the increased burden on caregivers.
- | Yescarta (axicabtagene ciloleucel) / Gilead
Journal: Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. (Pubmed Central) - Feb 27, 2023
A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complications, and early recognition and appropriate intervention will lead to the safe administration of these therapies, and ultimately improved outcomes for our patients.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis
LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING MONITORING IMPROVES EARLY RELAPSE DETECTION AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN FOLLICULAR LYMPHOMA PATIENTS (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1825;
It could be also used to detect false positives PET/TC assessments during follow-up. These results provide a rationale for designing ct DNA-based risk-adaptive clinical trials.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
ACCESS BARRIERS FOR ANTI-CD19+ CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY FOR NON-HODGKIN LYMPHOMA (NHL) ACROSS A LARGE COMMUNITY TRANSPLANT AND CELLULAR THERAPY NETWORK (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1241;
Disease-related factors were the primary reason, while age and financial coverage were not major contributors. Ongoing analyses will review the impact of other health determinants such as race and socioeconomic vulnerability.
- OUTCOMES FOR ANTI-CD19+ CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY FOR NON HODGKIN LYMPHOMA (NHL) ACROSS A LARGE COMMUNITY TRANSPLANT AND CELLULAR THERAPY NETWORK (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1230;
Outpatient administration is feasible in selected patients, but subsequent hospitalization needs to be anticipated. CRS, neurotoxicity, cytopenias and infection remain challenges, while disease progression was the commonest cause of death.
- Breyanzi (lisocabtagene maraleucel) / BMS
LISOCABTAGENE MARALEUCEL FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: FEASIBILITY, SAFETY AND EFFICACY IN A REAL-WORLD SETTING (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1225;
P1
Tocilizumab and steroids were administered to 5 (21.7%) and 7 (30.4%), respectively.Among infused patients (n=23), the best overall response (ORR) and complete response rates were 78.3% (ITT, 69.2%) and 56.5% (ITT, 50.0%), respectively. Our ITT analysis in an older patient population referred to our center for CD19 CAR-T therapy for R/R LBCL in the non-trial setting showed high rates of durable response after liso-cel with an acceptable safety profile.
- Breyanzi (lisocabtagene maraleucel) / BMS, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
A REPRODUCIBLE INFLAMMATORY BIOMARKER SIGNATURE IDENTIFIES NON-HODGKIN LYMPHOMA PATIENTS AT HIGH RISK OF CAR-T TREATMENT FAILURE ACROSS DIFFERENT COHORTS (Room 251) - Feb 11, 2023 - Abstract #EBMT2023EBMT_992;
Our ITT analysis in an older patient population referred to our center for CD19 CAR-T therapy for R/R LBCL in the non-trial setting showed high rates of durable response after liso-cel with an acceptable safety profile. Population CharacteristicsCenter 1 DevelopmentCenter 1 ValidationCenter 2 ValidationSample size, n17154141Disease, n (%)Large B-Cell Lymphoma171 (100)26 (48)141 (100)Mantle Cell Lymphoma0 (0)28 (52)0 (0)Age, median (IQR)66 (56
- Breyanzi (lisocabtagene maraleucel) / BMS
Lisocabtagene maraleucel vs standard of care as second-line treatment for large B-cell lymphoma (Room 12; Building 1; 3F 133+134) - Feb 8, 2023 - Abstract #JSTCT2023JSTCT_21;
- ||| Breyanzi (lisocabtagene maraleucel) / BMS
Liso-cel for r/r CLL💪🏾👏🏾👏🏾 Happy to see another potential option. Await full data especially for high-risk subgroup. (Twitter) - Jan 27, 2023
- ||||| Breyanzi (lisocabtagene maraleucel) / BMS
Clinical: Bristol Myers Squibb - Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia https://t.co/iGSoiJgeme (Twitter) - Jan 26, 2023
- |||| Breyanzi (lisocabtagene maraleucel) / BMS
Clinical: Press release on Liso-cel for CLL. Not much info but still good news for #CLL pts. #Cart https://t.co/pngl8ZEZED (Twitter) - Jan 26, 2023
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: TRANSCEND FL: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Jan 26, 2023
P2, N=213, Recruiting, Sponsor: Celgene
Population CharacteristicsCenter 1 DevelopmentCenter 1 ValidationCenter 2 ValidationSample size, n17154141Disease, n (%)Large B-Cell Lymphoma171 (100)26 (48)141 (100)Mantle Cell Lymphoma0 (0)28 (52)0 (0)Age, median (IQR)66 (56 Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: May 2028 --> Sep 2028
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
ASCT before Lymphocyte-apheresis Results in a More "Exhausted" T-cells Repertoire (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_109;
P
The use of CAR-T in second line in refractory or early relapse DLBCL patients, recently approved by FDA (Axi-cel and Liso-cel) and EMA (Axi-cel), would help to collect more "fit" Ly. Likewise, in high-risk DLBCL patients, timely pre-ASCT Ly-apheresis would be considered (Tisa-cel allow cryopreservation of Ly) in order to improve the quality of collected Lymphocyte for CAR-T manufacturing.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Cytotoxicity of CAR-T-cells from DLBCL Patients in High Resolution Microscopy (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_71;
Up to date, three different CD19 CAR (chimeric antigen receptor)-T-cell products, Axi-cel, Tisa-cel and Liso-cel have been tested in these patients as second- or third-line therapies and have shown promising outcome. Our analysis provides insights into the killing mechanism and the cytotoxic efficiency of CD19 CAR-T-cells isolated from DLBCL patients.
- Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Systematic Literature Review of Real-world Evidence on Axicabtagene-ciloleucel and Tisagenlecleucel (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_65;
Patients receiving CAR-T cell therapy in real-world settings had similar outcomes as patients who received CAR-T cell therapy in the pivotal clinical trials. Axi-cel led to improved OS and other effectiveness outcomes compared with tisa-cel in the real-world setting, although axi-cel was also associated with higher risks of CRS and ICANS.
- || Breyanzi (lisocabtagene maraleucel) / BMS, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Est ce qu'il y avait le petit cidre qui va bien? :) aussi la seule galette prise en photo au monde avec des prospectus pour Yestarta, Abecma, ou Breyanzi, well done! (Twitter) - Jan 21, 2023
- ||||| Breyanzi (lisocabtagene maraleucel) / BMS
CAR T-Cell Therapy, Gene therapy, Cytokine release syndrome: Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma https://t.co/QgEX4wxVdy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @Mohty_EBMT @Razan_Mohty (Twitter) - Jan 21, 2023
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: TRANSCEND FL: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Jan 17, 2023
P2, N=213, Recruiting, Sponsor: Celgene
Axi-cel led to improved OS and other effectiveness outcomes compared with tisa-cel in the real-world setting, although axi-cel was also associated with higher risks of CRS and ICANS. Trial completion date: Feb 2028 --> May 2028 | Trial primary completion date: Feb 2028 --> May 2028
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Jan 17, 2023
P1/2, N=62, Active, not recruiting, Sponsor: Celgene
Trial completion date: Feb 2028 --> May 2028 | Trial primary completion date: Feb 2028 --> May 2028 Trial completion date: Jul 2025 --> Jan 2023 | Trial primary completion date: Jul 2025 --> Jan 2023
- ||| Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) (clinicaltrials.gov) - Jan 13, 2023
P2, N=74, Completed, Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Trial completion date: Jul 2025 --> Jan 2023 | Trial primary completion date: Jul 2025 --> Jan 2023 Active, not recruiting --> Completed
- |||| Breyanzi (lisocabtagene maraleucel) / BMS
Biomarker, Tumor microenvironment, Gene Signature, Biopsy: Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel https://t.co/PFouAchzdV (Twitter) - Jan 7, 2023
- | Breyanzi (lisocabtagene maraleucel) / BMS, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov) - Jan 5, 2023
P2, N=20, Not yet recruiting, Sponsor: City of Hope Medical Center
- || Breyanzi (lisocabtagene maraleucel) / BMS, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
8-Lisocabtagene maraleucel (Breyanzi), büyük hücreli lenfomada ikinci basamak tedavi için onaylandı ve BCMA'ya yönelik idecabtagene vicleucel (Abecma), refrakter miyelom için onaylandı. (Twitter) - Dec 29, 2022
- || Breyanzi (lisocabtagene maraleucel) / BMS
Review, Journal: CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. (Pubmed Central) - Dec 28, 2022
We report the first case of diffuse large B-cell lymphoma (DLBCL) PTLD treated with lisocabtagene maraleucel and present a systematic literature review of SOTRs with PTLD treated with CD19 CAR-T therapy...Our analysis suggests that CD19 CAR-T therapy offers short-term effectiveness and manageable toxicity in SOTRs with R/R PTLD. Further investigation through larger datasets and prospective study is needed.
- ||| Breyanzi (lisocabtagene maraleucel) / BMS
Congrats @AJPortuguese @drjgauthier @EvanHallMD et al on great @BMTjournal case about liso-cel CAR-T in PTLD. When viruses create cancer by hiding inside host lymphoid cells, we respond by... using another virus to fight cancer by integrating into other host lymphoid cells 🤯 (Twitter) - Dec 27, 2022
- ||| Breyanzi (lisocabtagene maraleucel) / BMS
P3 data, Journal: Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. (Pubmed Central) - Dec 22, 2022
P3
These data show significant improvements in EFS, CR rate, and PFS for liso-cel over SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. (ClinicalTrials.gov; NCT03575351.).
- |||| Breyanzi (lisocabtagene maraleucel) / BMS
Clinical: Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study https://t.co/lYoKHnV2z9 (Twitter) - Dec 22, 2022
- | Journal, CAR T-Cell Therapy: Next-Generation Chimeric Antigen Receptor T-cells. (Pubmed Central) - Dec 21, 2022
Furthermore, CAR T-cell therapy is not broadly utilized in solid tumors due to various barriers. This review discusses the evolution of CAR T-cell therapies and how the "younger-generation" CAR T cells counteract these challenges to potentially broaden their applications in the future.
- || Review, Journal, CAR T-Cell Therapy: Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. (Pubmed Central) - Dec 21, 2022
Based on our PubMed literature review, we conclude that CAR T-cell therapy may benefit patients with CNS lymphoma with promising response rates and acceptable AE. However, definite conclusions cannot be drawn until data with a larger sample size is available.
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Setting of Care: A Retrospective Cohort Analysis of MCL and FL Patients in the United States (US) () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1151;
Median time from leukapheresis to CAR T-cell infusion was similar for MCL and FL in both infusion settings. Approximately 3 in 4 MCL pts and 2 in 3 FL pts experienced ≥1 observed CAR T-AE ≤90 d post-infusion.
- Successful Outpatient Treatment and Monitoring Following Administration of Multiple Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_918;
Median age was 69.5 (range 46-81). 60% of patients were male.
- Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B Cell Lymphomas () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_913;
A large proportion of post CAR T VTEs were line-associated DVTs. These findings may help identify patients at increased risk of VTE after CAR T-cell therapy and guide decisions on surveillance, choice of central access, or prophylactic anticoagulation.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_898;
CONCLUSION Severe cytopenias following CD19-CAR-T are common, with an estimated incidence of 25% and 80% incidence of profound thrombocytopenia and neutropenia, respectively. Our data suggest that clinical features, baseline counts, and the inflammatory profile before infusion are important determinants of cytopenia risk in CAR-T recipients.
- Breyanzi (lisocabtagene maraleucel) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead
Outpatient CAR T Cell Therapy Is Safe and Feasible in Patients with Lymphoma Treated in Non-University Medical Centers: A Multicenter, Retrospective Analysis. () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_897;
Median age of pts was 65 (26-86) with median HCT-CI score 2 (0-9), 42% had a score ≥ 3. DLBCL (n=32; 63%) was the most common histology treated.